이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Safety and Efficacy of MORA Cure LBP in Patients With Chronic Low Back Pain (MORACureLBP)

2026년 6월 17일 업데이트: EverEx Inc.

A Prospective, Randomized, Open-label, Multicenter, Controlled, Comparative, Confirmatory Trial of MORA Cure in Patients With Chronic Low Back Pain: 8-week Evaluation and 12-week Follow-up

This is a prospective, randomized, open-label, multicenter, controlled, comparative, confirmatory clinical trial to evaluate the safety and efficacy of MORA Cure LBP, a multidisciplinary digital therapeutic, in patients with chronic low back pain.

Eligible participants will be randomized in a 1:1 ratio to either the experimental group using MORA Cure LBP or the control group receiving exercise education and self-exercise materials. The treatment period is 8 weeks, followed by a 4-week observation period, for a total study period of 12 weeks from baseline. The primary efficacy endpoint is usual low back pain intensity during the past week measured by the 11-point Numeric Pain Rating Scale at Week 8.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

상세 설명

MORA Cure LBP is a software-based digital therapeutic intended to improve symptoms in patients with chronic low back pain by providing app-based exercise therapy and cognitive behavioral therapy. The investigational medical device consists of a patient mobile application and a clinician web program. Through the clinician web program, investigators can prescribe rehabilitation programs and monitor participants.

Participants assigned to the experimental group will use MORA Cure LBP for 8 weeks. Use of the device at least 3 times per week is recommended. After the 8-week treatment period, participants may continue to use available content during the follow-up observation period through Week 12.

Participants assigned to the control group will receive disease education, self-exercise education, and self-exercise materials. They will perform self-exercise and record exercise performance in a self-exercise diary.

Participants will attend 3 to 5 visits, including screening, baseline, Week 4, Week 8, and Week 12. The Week 4 visit may be conducted as a televisit. The Week 8 visit is the primary evaluation time point, and the Week 12 visit is the follow-up evaluation time point.

연구 유형

중재적

등록 (추정된)

156

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 대한민국
    • Gyeonggi-do
      • Guri-si, Gyeonggi-do, 대한민국
        • Hanyang University Guri Hospital
      • Gwangmyeong, Gyeonggi-do, 대한민국
        • Chung-Ang University Gwangmyeong Hospital
      • Uijeongbu-si, Gyeonggi-do, 대한민국
        • The Catholic University of Korea Uijeongbu St. Mary's Hospital
    • Korea
      • Seoul, Korea, 대한민국
        • Seoul National University Hospital
    • Seoul
      • Seoul, Seoul, 대한민국
        • Samsung Medical Center
      • Seoul, Seoul, 대한민국
        • Kangbuk Samsung Hospital
      • Seoul, Seoul, 대한민국
        • Nowon Eulji University Hospital
      • Seoul, Seoul, 대한민국
        • Seoul Asan Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria

  • Adults aged 19 years or older.
  • Participants with low back pain lasting for at least 12 weeks.
  • Participants with average low back pain intensity of 4 or higher on the Numeric Pain Rating Scale.
  • Participants who are able to undergo application-based treatment using a smartphone.
  • Participants who voluntarily decide to participate in the clinical trial and sign the informed consent form before the start of the trial.
  • Participants who, in the opinion of the principal investigator, are able to comply with the clinical investigation plan.

Exclusion Criteria

  • History of previous spinal surgery.
  • History of spinal injection treatment within 1 month before screening.
  • History of spinal trauma within 3 months before screening.
  • Lower limb muscle strength of 3 or less on manual muscle testing, or lower limb radiating pain accompanied by motor dysfunction.
  • Grade 2 or higher spondylolisthesis on radiographic imaging.
  • Scoliosis, defined as Cobb angle of 25 degrees or greater with a clear structural cause based on the principal investigator's judgment, or kyphosis, defined as lumbar lordosis angle less than 0 degrees.
  • Red flag signs, such as paralysis symptoms including bladder or bowel dysfunction, or sudden unexplained weight loss.
  • Tumor, infection, metabolic bone disease, cognitive impairment, fibromyalgia, systemic inflammatory disease, or systemic inflammatory disorder.
  • Any other systemic or psychiatric condition that, in the opinion of the principal investigator, limits exercise therapy.
  • Current use of opioid analgesics with potency equal to or greater than morphine for any other disease or low back pain, such as oxycodone, fentanyl, or pethidine. Participants may participate after a 14-day washout period if applicable.
  • Pregnant participants, participants planning pregnancy during the clinical trial, or participants unable to maintain contraception during the clinical trial.
  • Current participation in another clinical trial or planned participation in another clinical trial during this study.
  • Inability to communicate, difficulty following instructions, or any other condition that, in the opinion of the principal investigator, makes the participant unsuitable for this clinical trial.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: MORA Cure Digital Therapeutic
Participants assigned to the experimental group will use MORA Cure, a software-based digital therapeutic consisting of a patient mobile application and clinician web program. MORA Cure provides an 8-week app-based rehabilitation exercise program and cognitive behavioral therapy for chronic low back pain. Participants are recommended to use the device at least 3 times per week. After the 8-week treatment period, participants may use available content during the observation period through Week 12.
장치: MORA Cure LBP
MORA Cure is a digital therapeutic software intended to improve symptoms in patients with chronic low back pain by providing exercise therapy and cognitive behavioral therapy through a patient mobile application and clinician web program.
다른 이름들:
  • ETH-02K; ETH-02KW
활성 비교기: Exercise Education and Self-Exercise
Participants assigned to the control group will receive disease education, exercise education, and self-exercise materials. Participants will perform self-exercise and record exercise performance in a self-exercise diary.
행동: Exercise Education and Self-Exercise
Participants will receive education regarding chronic low back pain and self-exercise based on the control group exercise education materials. Participants will perform self-exercise and record exercise performance in a self-exercise diary.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Usual Low Back Pain Intensity at Weeks 4 and 12 Measured by the 11-point Numeric Pain Rating Scale
기간: Week 4 and Week 12 after baseline
Usual low back pain intensity during the past 1 week will be assessed using the 11-point Numeric Pain Rating Scale and compared between groups. The 11-point Numeric Pain Rating Scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate worse pain intensity.
Week 4 and Week 12 after baseline

2차 결과 측정

결과 측정
측정값 설명
기간
Worst Low Back Pain Intensity at Weeks 4, 8, and 12 Measured by the 11-point Numeric Pain Rating Scale
기간: Week 4, Week 8, and Week 12 after baseline
Worst low back pain intensity during the past 1 week will be assessed using the 11-point Numeric Pain Rating Scale and compared between groups. The 11-point Numeric Pain Rating Scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate worse pain intensity.
Week 4, Week 8, and Week 12 after baseline
Worst low back pain intensity during the past 1 week will be assessed using the 11-point Numeric Pain Rating Scale and compared between groups. The 11-point Numeric Pain Rating Scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the wor
기간: Week 4, Week 8, and Week 12 after baseline
Worst low back pain intensity during the past 1 week will be assessed using the 11-point Numeric Pain Rating Scale and compared between groups.
Week 4, Week 8, and Week 12 after baseline
Functional Disability at Weeks 4, 8, and 12 Measured by the Oswestry Disability Index
기간: Week 4, Week 8, and Week 12 after baseline
Functional disability related to low back pain will be assessed using the Oswestry Disability Index and compared between groups. The Oswestry Disability Index score ranges from 0 to 100, with higher scores indicating greater disability.
Week 4, Week 8, and Week 12 after baseline
Health-related Quality of Life at Weeks 4, 8, and 12 Measured by EQ-5D-5L
기간: Week 4, Week 8, and Week 12 after baseline
Health-related quality of life will be assessed using EQ-5D-5L and compared between groups. The EQ-5D-5L descriptive system includes 5 dimensions, each scored from 1 to 5. The total descriptive score ranges from 5 to 25, with higher scores indicating more problems and worse health-related quality of life. The EQ visual analogue scale ranges from 0 to 100, with higher scores indicating better self-rated health status.
Week 4, Week 8, and Week 12 after baseline
Change From Baseline in Usual Low Back Pain Intensity Measured by the 11-point Numeric Pain Rating Scale
기간: Baseline to Week 4, Week 8, and Week 12
Change from baseline in usual low back pain intensity during the past 1 week will be assessed using the 11-point Numeric Pain Rating Scale and compared between groups. The 11-point Numeric Pain Rating Scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate worse pain intensity. A negative change from baseline indicates improvement.
Baseline to Week 4, Week 8, and Week 12
Change From Baseline in Worst Low Back Pain Intensity Measured by the 11-point Numeric Pain Rating Scale
기간: Baseline to Week 4, Week 8, and Week 12
Change from baseline in worst low back pain intensity during the past 1 week will be assessed using the 11-point Numeric Pain Rating Scale and compared between groups. The 11-point Numeric Pain Rating Scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate worse pain intensity. A negative change from baseline indicates improvement.
Baseline to Week 4, Week 8, and Week 12
Change From Baseline in Functional Disability Measured by the Oswestry Disability Index
기간: Baseline to Week 4, Week 8, and Week 12
Change from baseline in functional disability related to low back pain will be assessed using the Oswestry Disability Index and compared between groups. The Oswestry Disability Index score ranges from 0 to 100, with higher scores indicating greater disability. A negative change from baseline indicates improvement.
Baseline to Week 4, Week 8, and Week 12
Change From Baseline in Health-related Quality of Life Measured by EQ-5D-5L
기간: Baseline to Week 4, Week 8, and Week 12
Change from baseline in health-related quality of life will be assessed using EQ-5D-5L and compared between groups. The EQ-5D-5L descriptive system includes 5 dimensions, each scored from 1 to 5. The total descriptive score ranges from 5 to 25, with higher scores indicating more problems and worse health-related quality of life. The EQ visual analogue scale ranges from 0 to 100, with higher scores indicating better self-rated health status.
Baseline to Week 4, Week 8, and Week 12

기타 결과 측정

결과 측정
측정값 설명
기간
Treatment Compliance Percentage at Weeks 4 and 8
기간: Week 4 and Week 8 after baseline
Treatment compliance will be assessed as a percentage and compared between the MORA Cure group and the control group. In the MORA Cure group, compliance will be assessed using data from the clinician web program. In the control group, compliance will be assessed using the self-exercise diary. Compliance ranges from 0% to 100%, with higher percentages indicating better treatment compliance.
Week 4 and Week 8 after baseline
Psychological Status at Weeks 8 and 12 Measured by the Patient Health Questionnaire-9
기간: Week 8 and Week 12 after baseline
Depression symptoms will be assessed using the Patient Health Questionnaire-9 and compared between groups. The Patient Health Questionnaire-9 score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms.
Week 8 and Week 12 after baseline
Pain Catastrophizing at Weeks 8 and 12 Measured by the Pain Catastrophizing Scale
기간: Week 8 and Week 12 after baseline
Pain catastrophizing will be assessed using the Pain Catastrophizing Scale and compared between groups. The Pain Catastrophizing Scale score ranges from 0 to 52, with higher scores indicating greater pain catastrophizing.
Week 8 and Week 12 after baseline
Spinal Muscle Endurance Duration at Weeks 8 and 12 Measured by the Prone Bridge Test
기간: Week 8 and Week 12 after baseline
Spinal muscle endurance will be assessed using the prone bridge test and compared between groups. The outcome will be measured as the duration that the participant can maintain the prone bridge position, recorded in seconds. Higher values indicate better spinal muscle endurance.
Week 8 and Week 12 after baseline
Radiographic Spinal Alignment Parameters at Week 8 Measured by Whole-spine Lateral X-ray
기간: Week 8 after baseline
Radiographic spinal alignment will be assessed using whole-spine lateral X-ray and compared between groups. The parameters include lumbar lordosis, pelvic tilt, pelvic incidence, sacral slope, and sagittal vertical axis. Angular parameters will be measured in degrees, and sagittal vertical axis will be measured in millimeters.
Week 8 after baseline
Incidence of Adverse Events
기간: From informed consent through Week 12 and applicable safety follow-up period
Adverse events, adverse device effects, serious adverse events, and serious adverse device effects will be collected and summarized by treatment group. For adverse device effects, follow-up will be performed as applicable until 14 days after the last use of the investigational medical device.
From informed consent through Week 12 and applicable safety follow-up period

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

EverEx Inc.

수사관

  • 수석 연구원: Cho Jae Hwan, MD, PhD, Asan Medical Center

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 3월 19일

기본 완료 (추정된)

2026년 8월 20일

연구 완료 (추정된)

2026년 9월 30일

연구 등록 날짜

최초 제출

2026년 6월 11일

QC 기준을 충족하는 최초 제출

2026년 6월 17일

처음 게시됨 (실제)

2026년 6월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 6월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 6월 17일

마지막으로 확인됨

2026년 6월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • EX-CU-LB-02

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다